Diego Curtò Federica Tomatis Sara Gastoldi Miriam Galbusera Marina Noris Federico Raimondi Ferdinando Luca Lorini Anna Falanga Marina Marchetti Giuseppe Remuzzi Piero Ruggenenti
10.3389/fimmu.2021.711915
Front Immunol
2021 Jun 30;12:711915.
covid-19 case report coagulation biomarkers convalescent antibodies double filtration plasmapheresis hypercoagulability immunosuppression rituximab
CC BY
https://pubmed.ncbi.nlm.nih.gov/34276706/
Antibodies, Neutralizing / therapeutic use Antibodies, Viral / therapeutic use COVID-19 / therapy Immunization, Passive / methods Immunocompromised Host Immunoglobulin G / therapeutic use Plasmapheresis / methods SARS-CoV-2 / genetics
Antibodies, Neutralizing / therapeutic use Antibodies, Viral / therapeutic use COVID-19 / therapy Immunization, Passive / methods Immunocompromised Host Immunoglobulin G / therapeutic use Plasmapheresis / methods SARS-CoV-2 / genetics Case Reports Research Support, Non-U.S. Gov't Antineoplastic Agents, Immunological / adverse effects Antiviral Agents / therapeutic use COVID-19 / immunology COVID-19 / virology COVID-19 Serotherapy Female Humans Immunity / drug effects Lymphoma, Large B-Cell, Diffuse / drug therapy Middle Aged RNA, Viral / genetics Rituximab / adverse effects Treatment Outcome Antibodies, Neutralizing Antibodies, Viral Antineoplastic Agents, Immunological Antiviral Agents Immunoglobulin G RNA, Viral Rituximab
PMC8278474
34276706
Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis
2021